About Scigen
SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which can allow for faster entry into the market, as biosimilar products have undergone much of the clinical development and trials required to bring new drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market
SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange. SciGen is headquartered in Singapore, with offices also in Australia, USA, India, Korea, Vietnam, Hong Kong, Israel and Philippines, joint ventures in China, and partnership on Indonesia, Israel, Poland, Thailand, Taiwan, Pakistan and the Netherlands.
- Industry : Pharma
